Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Should This Be Concerning...

<< Previous

Bullboard Posts

Next >>

Comment by Matteo1234on Jul 24, 2020 2:35am

213 Views

Post# 31312512

RE:Should This Be Concerning...

I know the feeling brother. I bought the private placement. Have faith. Your main issue is that you have millions of shares. Therefore a penny drop on a million is $10,000. But so is the gain on the way up. Look at gwph it's now a billion dollar company. How you think it started. Long-term play. No fear.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing